Advertisement

Topics

DVAX Surges On FDA Panel Vote, CYTR On Watch, EC Approves New HCV Drugs

23:33 EDT 30 Jul 2017 | RTTNews

Today's Daily Dose brings you news about approval of AbbVie's Maviret and Gilead's Vosevi for the treatment of chronic hepatitis C virus by the European Commission; CytRx's $356 million licensing deal with privately-held NantCell; FDA panel support for Dynavax's hepatitis B vaccine and the progress of Tenax's heart drug Levosimendan.

Original Article: DVAX Surges On FDA Panel Vote, CYTR On Watch, EC Approves New HCV Drugs

NEXT ARTICLE

More From BioPortfolio on "DVAX Surges On FDA Panel Vote, CYTR On Watch, EC Approves New HCV Drugs"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...